Literature DB >> 27567689

The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models.

Brandon J Manley1, Daniel M Tennenbaum1, Emily A Vertosick2, James J Hsieh3, Daniel D Sjoberg2, Melissa Assel2, Nicole E Benfante1, Seth A Strope4, Eric Kim4, Jozefina Casuscelli1, Maria F Becerra1, Jonathan A Coleman1, Abraham Ari Hakimi1, Paul Russo5.   

Abstract

PURPOSE: To externally evaluate a preoperative points system and a preoperative nomogram, both created to assess time to death after cytoreductive nephrectomy (CN).
MATERIALS AND METHODS: We identified 298 patients who underwent CN at our institution, a tertiary cancer center, between 1989 and 2015. To validate the points system, we compared reported overall survival (OS) for each criterion to observed OS in our cohort. To evaluate the nomogram, we prognosticated risk of death at 6 months after surgery for 280 patients with sufficient follow-up in our cohort and evaluated discrimination using area under the curve (AUC) and calibration. Decision curve analysis was performed to assess clinical utility of the nomogram.
RESULTS: Significant differences in OS were observed between patients with and without 5 of 7 criteria on univariate analysis: low albumin (P<0.0001), high lactate dehydrogenase (P = 0.002), liver metastasis (P = 0.004), retroperitoneal lymphadenopathy (P = 0.002), and supradiaphragmatic lymphadenopathy (P = 0.019). Discrimination from the preoperative model, predicting death within 6 months of surgery was lower in our cohort (AUC = 0.65, 95% CI: 0.52-0.79) than the original publication (AUC = 0.76). Decision curve analysis demonstrated little benefit for applicability.
CONCLUSIONS: Five previously defined risk factors are predictive of decreased OS after CN in our cohort. We found lower discrimination using the preoperative model and minimal clinical utility according to decision analysis in our study cohort. These findings suggest the need for improved models to aid patient stratification and consequent treatment choice.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mortality; Neoplasm metastasis; Nephrectomy; Prognosis; Renal cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27567689      PMCID: PMC5154851          DOI: 10.1016/j.urolonc.2016.07.010

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  15 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

3.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

4.  A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Authors:  Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Igor Frank; Eugene D Kwon; Jaime R Merchan; Michael L Blute
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

5.  Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Vitaly Margulis; Shahrokh F Shariat; Yury Rapoport; Michael Rink; Daniel D Sjoberg; Nizar M Tannir; E Jason Abel; Stephen H Culp; Pheroze Tamboli; Christopher G Wood
Journal:  Eur Urol       Date:  2012-11-23       Impact factor: 20.096

6.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Authors:  Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

7.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

Review 9.  A river model to map convergent cancer evolution and guide therapy in RCC.

Authors:  Elizabeth Y Wei; James J Hsieh
Journal:  Nat Rev Urol       Date:  2015-11-03       Impact factor: 14.432

10.  Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.

Authors:  Simon L Conti; I-Chun Thomas; Judith C Hagedorn; Benjamin I Chung; Glenn M Chertow; Todd H Wagner; James D Brooks; Sandy Srinivas; John T Leppert
Journal:  Int J Cancer       Date:  2014-05-01       Impact factor: 7.396

View more
  8 in total

1.  External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Lorenzo Marconi; Roderick de Bruijn; Erik van Werkhoven; Christian Beisland; Kate Fife; Axel Heidenreich; Anil Kapoor; Jose Karam; Caroline Kauffmann; Tobias Klatte; Boerje Ljungberg; Surena Matin; Daniel Sjoberg; Michael Staehler; Grant D Stewart; Simon Tanguay; Robert Uzzo; Sarah Welsh; Lori Wood; Chris Wood; Axel Bex
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

2.  The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.

Authors:  Renzo G DiNatale; Wanling Xie; Maria F Becerra; Andrew W Silagy; Kyrollis Attalla; Alejandro Sanchez; Roy Mano; Julian Marcon; Kyle A Blum; Nicole E Benfante; Martin H Voss; Robert J Motzer; Jonathan Coleman; Toni K Choueiri; Ed Reznik; Paul Russo; Daniel Y C Heng; A Ari Hakimi
Journal:  Eur Urol Oncol       Date:  2019-11-14

Review 3.  The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.

Authors:  Roy Mano; Nikhil Gopal; A Ari Hakimi
Journal:  Curr Opin Urol       Date:  2019-09       Impact factor: 2.309

4.  The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Authors:  Charles C Peyton; E Jason Abel; Juan Chipollini; David C Boulware; Mounsif Azizi; Jose A Karam; Vitaly Margulis; Viraj A Master; Surena F Matin; Jay D Raman; Wade J Sexton; Christopher G Wood; Philippe E Spiess
Journal:  Eur Urol Focus       Date:  2018-09-08

5.  Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.

Authors:  Andrew W Silagy; Ritesh R Kotecha; Stanley Weng; Arturo Holmes; Nirmish Singla; Roy Mano; Kyrollis Attalla; Kate L Weiss; Renzo G DiNatale; Sujata Patil; Jonathan A Coleman; Robert J Motzer; Paul Russo; Martin H Voss; A Ari Hakimi
Journal:  Cancer       Date:  2021-07-19       Impact factor: 6.860

Review 6.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

7.  Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?

Authors:  Jacob J Adashek; Yumeng Zhang; William Paul Skelton; Alyssa Bilotta; Jad Chahoud; Logan Zemp; Jiannong Li; Jasreman Dhillon; Brandon Manley; Philippe E Spiess
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

8.  Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.

Authors:  Ekaterina Laukhtina; Victor M Schuettfort; David D'Andrea; Benjamin Pradere; Fahad Quhal; Keiichiro Mori; Reza Sari Motlagh; Hadi Mostafaei; Satoshi Katayama; Nico C Grossmann; Pawel Rajwa; Pierre I Karakiewicz; Manuela Schmidinger; Harun Fajkovic; Dmitry Enikeev; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-10-20       Impact factor: 4.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.